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OBJECTIVES This study assessed the effects of biventricular pacing (BVP) on ventricular function,
functional status, quality of life and hospitalization in patients with congestive heart failure
(CHF), prior atrioventricular (AV) junction ablation and right ventricular (RV) pacing
performed for chronic atrial fibrillation (AF).
BACKGROUND Although the benefit of BVP in CHF should theoretically extend to the patient with chronic
RV pacing and AF, to our knowledge, no study has determined the effects of BVP on
symptoms and ventricular function in these patients. This patient population allows for the
evaluation of ventricular resynchronization independent of any BVP-induced changes on the
AV interval.
METHODS Twenty consecutive patients with severe CHF (ejection fraction 0.35, New York Heart
Association [NYHA] functional class III or IV), prior AV junction ablation and RV pacing
performed for permanent AF of at least six months’ duration were studied. Electrocardio-
grams, echocardiograms, functional status evaluations and quality of life surveys were
completed before and at three to six months after implant.
RESULTS The NYHA functional classification improved 29% (p  0.001). The left ventricular (LV)
ejection fraction increased 44% (p  0.001), the LV diastolic diameter decreased 6.5% (p 
0.003) and the end-systolic diameter decreased 8.5% (p  0.01). The number of hospital-
izations decreased by 81% (p  0.001). The scores on the Minnesota Living with Heart
Failure survey improved by 33% (p  0.01).
CONCLUSIONS We conclude that BVP improves the LV function and the symptoms of CHF in patients with
permanent AF and chronic RV pacing. These benefits are comparable to those described for
patients in sinus rhythm suggesting that BVP acts through ventricular resynchronization
rather than optimization of the AV delay. (J Am Coll Cardiol 2002;39:1258–63) © 2002
by the American College of Cardiology Foundation
Many patients with severe congestive heart failure (CHF)
develop chronic atrial fibrillation (AF). The onset of AF
eliminates regular atrioventricular (AV) transport, worsen-
ing cardiac performance in these patients with ventricular
dysfunction. Radiofrequency ablation of the AV junction
and right ventricular (RV) pacing improves ventricular
function, symptoms and quality of life in patients with AF
refractory to drug therapy for ventricular rate control (1,2).
However, some patients may have persistent or progressive
CHF symptoms after junction ablation and conventional
RV apical pacing. The abnormal left ventricular (LV)
activation sequence produced by cardiac pacing from the
RV apex may contribute to the lack of improvement
observed in some patients after ablate-pace therapy.
Right ventricular apical pacing produces a LV conduction
pattern similar to a left bundle branch block (LBBB), with
a posterior and superior initial and total QRS vector with a
prolonged QRS duration. Consequences of RV pacing
include paradoxical septal motion and reduction in ejection
fraction with a detrimental effect on systolic pressure and
cardiac output (3–5). Chronic RV apical pacing produces
geometric changes that appear similar on echocardiography
to changes associated with intrinsic LBBB. Because RV
apical pacing induces the same vector electrocardiographic
patterns and functional abnormalities present during intrin-
sic LV conduction delay, apical pacing may worsen symp-
toms and functional status when used in the patient with
pre-existing ventricular dysfunction.
Cardiac resynchronization with biventricular pacing
(BVP) reverses the mechanical abnormalities associated
with severe ventricular conduction delay and improves
patient symptoms, functional capacity, exercise time and
quality of life (6,7). The mechanisms by which BVP
improves symptoms in CHF include normalization of
ventricular wall motion, optimization of AV filling and
reduction of mitral regurgitation in the patient with LV
dysfunction and conduction delay with a QRS interval
exceeding 130 ms (8–14). Published clinical trials of BVP
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exclude patients with chronic RV pacing or AF. Cardiac
resynchronization for ventricular dysfunction and conduc-
tion delay should theoretically extend to the patient with
chronic AF. However, to our knowledge, no study to date
has described the impact of the therapy in these patients.
Testing the effectiveness of BVP in patients with AF and
chronic RV pacing after AV junction ablation provides an
opportunity to determine whether cardiac resynchronization
improves symptoms of CHF and ventricular function inde-
pendent of any atrial contribution to cardiac output. This
investigation evaluated whether BVP improves ventricular
function, functional status, quality of life and decreases
hospitalization in patients with CHF and chronic AF.
METHODS
Patient population. The authors evaluated 20 patients at
Crawford Long Hospital and Emory Hospital of Emory
University. The group includes consecutive patients with
severe CHF, permanent AF, prior AV junction ablation and
RV pacing for at least six months prior to enrollment.
Inclusion criteria identified subjects with LV dysfunction
and ejection fraction 0.35, CHF with severe functional
impairment of New York Heart Association (NYHA)
functional class III or IV and CHF symptoms refractory to
standard medical therapy. Baseline patient evaluation in-
cluded a history and physical examination, 12-lead electro-
cardiogram, and an assessment of LV function by echocar-
diography. We identified the frequency of unscheduled
hospitalization for worsening CHF during the year prior to
and after enrollment. Ambulatory visits were not included.
Patients also completed the Minnesota Living with Heart
Failure Quality of Life Survey (15). Table 1 displays the
demographic and clinical characteristics at entry.
Device implantation. All subjects underwent a procedure
to revise the RV pacing system to BVP in the cardiac
electrophysiology laboratory. A conscious sedation protocol
approved by Emory University provides patient comfort,
and local infiltration of lidocaine (1%) provided anesthesia
during the procedure. The surgical implant procedure in-
volved incision into and dissection of the chronically im-
planted pacemaker pocket to expose the generator and lead.
We described in detail the technical aspects of the upgrade
procedure in a previous publication (16).
The authors predetermined a preference for a lateral,
anterolateral or posterolateral LV vein as a target for the
final pacing lead position to separate the RV and LV
electrodes as much as possible. Introduction of a commer-
cially available, bipolar (Medtronic 4024, Minneapolis,
Minnesota) or unipolar (Medtronic 4023) (65 or 85 cm
length) pacing lead through the sheath and into the desired
vein provided LV free-wall stimulation. We sequentially
connected the RV and LV leads to a bipolar Y-adapter
(Medtronic 2872) and inserted the Y-adapter into a single
chamber rate-responsive pulse generator. We programmed
the single chamber generator with the Y-adapter to the
VVIR mode. We replaced any chronically implanted pulse
generator estimated to have less than half of its battery
service life remaining to prevent early pulse generator
depletion by potentially increased current loads from parallel
connection of two ventricular leads into the Y-adapter.
Clinical follow-up and end points. Predischarge pace-
maker interrogation and 12-lead electrocardiogram con-
firmed stability of RV and LV pacing thresholds. Initial
follow-up evaluations at three to six months included repeat
echocardiography, device interrogation with threshold
checks, quality of life survey, physical examination and chest
radiography. Return visits to the pacemaker clinic were
performed at six-month intervals thereafter. End points for
analysis included echocardiographic ventricular ejection
fraction and dimensions, NYHA functional class, quality of
life scores on the University of Minnesota Living with
Abbreviations and Acronyms
AF  atrial fibrillation
AV  atrioventricular
BVP  biventricular pacing
CHF  congestive heart failure
LBBB  left bundle branch block
LV  left ventricular
MUSTIC  Multisite Stimulation in Cardiomyopathy
Study
NYHA  New York Heart Association
PAVE  Post AV Node Ablation Evaluation
RV  right ventricular
Table 1. Baseline Characteristics
Characteristic No.
Age (yrs) 69.9  10.8
Gender (M/F) 17/3
Duration of RV pacing (months) 26.4  12.2
Causes of CHF
Ischemic 11 (55%)
Idiopathic 5 (25%)
Hypertension 3 (15%)
Valvular 1 (5%)
Baseline medications
ACE inhibitor/receptor blocker 18 (90%)
Beta-blocker 5 (25%)
Diuretic 19 (95%)
Digoxin 12 (60%)
NYHA functional class
III 12 (60%)
IV 8 (40%)
Minnesota LWHF survey score 77.8  23.6
Hospitalizations (1 yr before BVP) 1.9  0.8
QRS width (ms) 213  40
LVEF (%) 21.5  6.9
LVEDd (mm) 67.9  8.3
LVESd (mm) 56.3  9.8
ACE  angiotensin converting enzyme; BVP  biventricular pacing; CHF 
congestive heart failure; LVEDd left ventricular end-diastolic dimension; LVEF
left ventricular ejection fraction; LVESd  left ventricular end-systolic dimension;
LWHF  Living With Heart Failure survey; NYHA  New York Heart Associa-
tion; RV  right ventricular.
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Heart Failure Quality of Life survey and frequency of
hospitalization prior to and after pacemaker revision to
BVP.
Statistical analysis. Numerical results are expressed in the
text as the mean  1 SD. The differences between the
continuous variables before and after BVP were evaluated
using a paired t test. Changes in NYHA functional class as
a result of the procedure were assessed using contingency
table analysis. A p value 0.05 was used to indicate
statistical significance.
RESULTS
Clinical characteristics. The procedure successfully re-
vised the chronic RV pacing system to BVP in all 20
patients. All 20 patients were alive at the follow-up evalu-
ation and are included in the analysis. All patients com-
pleted follow-up evaluation between three to six months
after implant. Left ventricular capture threshold was 1.9 
1.0 V, with a lead impedance of 694.8  144.6 ohms. Final
LV lead position included 4 electrodes in the anterolateral
vein, 6 in the lateral vein and 10 in the posterolateral vein.
We observed no procedural complications.
Of the 20 patients, 17 remain alive to date, during a mean
follow-up period of 17.3 4.5 months. One patient died 18
months after pacemaker revision from bacterial peritonitis
complicating long-term peritoneal dialysis. Two other pa-
tients died over a year after implantation of worsening
CHF. Another patient developed ventricular tachycardia
three months after the revision requiring removal of the
pacing system and insertion of a transvenous defibrillator
with BVP capability.
Clinical outcome. The NYHA functional classification
improved from 3.4  0.5 to 2.4  0.6 (chi square  20.4,
p  0.001) (Fig. 1). The number of hospitalizations
required one year prior to the procedure decreased from an
average of 1.9  0.8 to 0.4  0.6 at one year postprocedure
(p  0.001) (Fig. 2). The scores on the Minnesota Living
with Heart Failure Quality of Life survey improved from
78  24 to 52  23 (p  0.01).
Electrocardiographic and echocardiographic outcome.
The QRS duration decreased from 213  40 ms to 172 
31 ms (p 0.0001). Repeat echocardiography at three to six
months after the upgrade procedure showed a mean LV
ejection fraction of 30.9  11.5%, an increase from a
baseline of 21.5 6.9% (p 0.001) (Fig. 3). The mean LV
diastolic diameter decreased from 67.9 8.3 mm to 63.5
7.7 mm (p  0.003) and the end-systolic diameter from
56.3  9.8 mm to 51.5  10.9 mm (p  0.01).
DISCUSSION
Conversion to BVP provides cardiac resynchronization to
the patients in this study with chronic RV pacing for AF.
Our analysis provides evidence that in the patient with
CHF, AF and chronic RV apical pacing, conversion to BVP
reverses asynchrony, improves ventricular performance and
dimensions, quality of life and symptoms of CHF in the
same manner as described in patients with sinus rhythm and
LBBB who undergo BVP. We detected significant im-
provement in functional class, increased ejection fraction, a
decrease in end-systolic and end-diastolic diameters, a
decrease in the number of hospitalizations and improved
Figure 1. Improvement in New York Heart Association (NYHA) functional class after upgrade from a RV pacemaker to a biventricular pacemaker
(BVP).
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quality of life scores in this population with severe CHF and
chronic RV pacing.
Cause of benefit of BVP in patients with chronic AF and
RV pacing. Assessing the benefit of BVP in the patient with
AF and complete AV block after junction ablation provides a
relevant model to examine the isolated effect of BVP on
ventricular function. Absence of any active atrial transport
permits an assessment of the isolated impact of resynchroni-
zation therapy on cardiac performance independent of any AV
timing considerations. Atrioventricular block produced by
catheter ablation ensures that all ventricular activation occurs
through the pacing leads, without any possible fusion that
might contaminate an assessment of the pacing therapy.
Obtaining the echocardiographic baseline LV and clinical data
prior to upgrade but chronically after junction ablation elimi-
nates the possibility that regularizing ventricular rate and filling
Figure 2. Reduction in number of hospitalizations required 1 year prior to the upgrade from a RV pacemaker to a biventricular pacemaker (BVP) compared
to 1 year after.
Figure 3. Improvement in ejection fraction (%) after upgrade from a RV to a biventricular pacemaker (BVP).
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interval acutely contributed to the observed improvement in
ejection fraction after upgrade to BVP.
Several studies have demonstrated improved LV systolic
function in patients with impaired LV function after AV
node ablation and RV pacing (17–19). Some investigators
have suggested that atrial synchronized BVP with echocar-
diographic and Doppler-guided programming of the AV
delay optimizes left atrial to LV flow (20,21) and improves
ventricular output. They attribute a large portion of the
benefit of BVP to the impact of optimizing atrial contribu-
tion to cardiac output (20,21). Because the patients in our
study underwent catheter ablation long before upgrade to
BVP, one cannot attribute the improvement in clinical and
echocardiographic parameters simply to regularization of
the ventricular response to AF, as reported often after
junction ablation and standard RV apical pacing (17–19).
Comparison to other trials. The use of angiotensin-
converting enzyme inhibitors or receptor blockers in this
study approaches the use in previously reported trials of
BVP. The use of beta-blockers in our patients exceeds the
use of the drug in early studies such as the Medtronic Inc.
InSync study (6) and approaches the use in the Multisite
Stimulation in Cardiomyopathy (MUSTIC) (7) study. This
study population includes a larger proportion (40%) of
patients with NYHA functional class IV symptoms than the
other published trials of BVP. Including a larger proportion
of patients with severe CHF may increase the probability of
detecting a treatment effect from BVP. The other clinical
characteristics of the group studied compare favorably with
the patients described in previous trials of BVP, except for
the presence of AF.
This study evaluates the impact of the upgrade procedure
on the same end points of symptomatic improvement and
ventricular performance reported in Pacing Therapies for
CHF (PATH-CHF) (8), Medtronic Inc. InSync (6),
MUSTIC (7) and Multicenter InSync Randomized Clinical
Evaluation (MIRACLE) (9). The results find similar im-
provement in functional status, quality of life scores, echo-
cardiographic assessment of ventricular dimensions and
ejection fraction.
Published clinical trials of BVP excluded patients with
AF and chronic RV pacing which prevents any objective
assessment of the benefit of BVP to the patient without
active atrial transport. Therefore, until now, we could not
extrapolate the benefit of cardiac resynchronization in CHF
to the large patient population with CHF and chronic RV
pacing for AF. Two published studies up to now have
looked at BVP in patients with AF (22,23). In both of these
studies, the AV node was ablated at the time of BVP
implantation. All the patients in our study underwent
ablation at least six months before BVP implantation, with
a mean duration of over two years. Therefore, our results
cannot be attributed to the acute beneficial effects of pacing
in chronic AF due to the optimization of left atrial to LV
filling or to heart rate control (17–19). Other clinical trials
will further examine the impact of BVP in the patient with
AF. The results from the MUSTIC AF subgroup are
preliminary (23). The ongoing Post AV Node Ablation
Evaluation (PAVE) (24) study also addresses the role of
BVP and LV pacing in improving ventricular function in
the patient with AF.
Study limitations. We could not utilize a crossover analysis
of BVP similar to our comparison of RV apical pacing to
septal pacing (25) in patients with AF after junction
ablation. The patients included in the present study under-
went chronic RV pacing prior to enrollment that might have
produced ventricular structural and functional changes that
might not quickly reverse during a short crossover interval.
Another possible model utilizing a dual-chamber pulse
generator with the LV lead in the atrial port and the RV
lead in the ventricular port with random programming to
AAIR, DDDR and VVIR modes would permit an elegant
comparison of RV, LV and BVP in the same patient. The
limited long-term follow-up available on LV pacing dis-
couraged our use of that design. The PAVE study will
compare results of the three pacing sites in a larger patient
population.
Another limitation of the study is that patients were
compared before and after upgrade of the device. The
Minnesota Living with Heart Failure questionnaire intro-
duced by Rector et al. (15) is commonly used for the
assessment of patients with heart failure. Although its
clinical value has been established (26), we cannot rule out
the possibility of the placebo effect since there was no
control group in our study. In other studies of BVP, quality
of life values have shown some improvement in patients
who received control therapy (9). Thus, quality of life may
show improvement even when no active therapy is deliv-
ered.
CONCLUSIONS
We conclude that BVP improves symptoms of CHF by
improving ventricular function in the absence of AV trans-
port. One cannot attribute the overall benefit of BVP simply
to optimization of left atrial to LV filling. One should
consider BVP in the patient with AF, LV dysfunction and
severe CHF. One should not exclude patients with AF as
candidates for BVP when AV conduction can be controlled
with medications or junctional ablation.
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